As we age, our cells accumulate genetic changes—mutations—some of which open the door to cancer. Scientists call these ...
Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results from the Phase 1b Beamion LUNG-1 trial of HERNEXEOS® (zongertinib tablets) in treatment-naïve ...
PYNNACLE enrolled heavily pretreated TP53 Y220C–mutant ovarian cancer (median four prior lines), including platinum-resistant ...
Aortic aneurysms are characterized by abnormal enlargement of the aorta, the primary artery responsible for carrying blood ...
Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results from the Phase 1b Beamion LUNG-1 trial of HERNEXEOS (zongertinib tablets) in ...
Finally, this thesis demonstrates that inherited predisposition, such as germline mutations in the TP53 gene, plays an important role in how treatment influences the evolution of second cancers. These ...
The idea that modern humans inherited DNA from Neanderthal ancestors is one of the 21st century’s most celebrated discoveries ...
A clinician-led approach boosts genetic testing among relatives of people with newly detected pathogenic variants — and could help close a gap in hereditary cancer prevention.
An investigational targeted therapy doubled survival compared with standard chemotherapy for pretreated individuals with ...
The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.
New experimental medications seem to extend survival with the hard-to-treat cancer.
First, the good news. Among Americans under 50, the overall cancer mortality has plummeted by 44% over the last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results